<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-12-03" updated="2019-12-02">
  <drugbank-id primary="true">DB11230</drugbank-id>
  <name>Magnesium Aluminum Silicate</name>
  <description>Magnesium aluminum silicate is a naturally occurring mineral obtained from silicate ores of the montmorillonite group [A32782]. It is refined to a powder for use in cosmetic and pharmaceutical applications as an absorbent, anticaking agent, opacifying agent, viscosity-increasing agent, suspending agent, tablet and capsule disintegrant, and&#13;
tablet binder. It also has antacid properties and is used as a component of some over the counter antacid medications.</description>
  <cas-number>1327-43-1</cas-number>
  <unii>6M3P64V0NC</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32782</ref-id>
        <pubmed-id>12851164</pubmed-id>
        <citation>Elmore AR: Final report on the safety assessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller's earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite. Int J Toxicol. 2003;22 Suppl 1:37-102.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Magnesium aluminum silicate is used as an over the counter antacid for the self-treatment of heartburn, sour stomach, or acid indigestion [FDA Label].</indication>
  <pharmacodynamics>Magnesium aluminum silicate neutralizes excess acid in the stomach to reduce or eliminate symptoms of heartburn, sour stomach, or acid indigestion [FDA Label]</pharmacodynamics>
  <mechanism-of-action>Magnesium aluminum silicate reacts with acid in the stomach to increase the pH.</mechanism-of-action>
  <toxicity>The LD50 in mice is considered to be &gt;50000 mg/kg with oral suspensions of magnesium aluminum silicate [A32782]. The dermal LD50 is considered to be &gt;3.5 g/kg observed in rabbits. Magnesium aluminum silicate produced mild skin irritation. In a 90 day study in rats, animal fed a diet with 20% magnesium aluminum silicate had slightly stunted growth. With 5% and 10% the rats had increased silicone content in the spleen. At 2% one male rat died and at 10% one male and female rat died. These rats had fibrous exudates in the thorax and hemorrhage in the lungs with evidence of infection. No evidence of teratogenicity or mutagenicity was found in the appropriate studies.</toxicity>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="latin" coder="">Aluminii magnesii silicas</synonym>
    <synonym language="english" coder="">Aluminium magnesium silicate</synonym>
    <synonym language="english" coder="">Aluminium magnesium silicate hydrate</synonym>
    <synonym language="english" coder="">Aluminium magnesium silicate polyhydrate</synonym>
    <synonym language="english" coder="">Aluminum magnesium silicate</synonym>
    <synonym language="english" coder="">Magnesium aluminium silicate</synonym>
    <synonym language="english" coder="">Magnesium aluminium silicate hydrate</synonym>
    <synonym language="english" coder="">Magnesium aluminum silicate hydrate</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>Veegum</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids</category>
      <mesh-id>D000143</mesh-id>
    </category>
    <category>
      <category>Acids, Noncarboxylic</category>
      <mesh-id>D000148</mesh-id>
    </category>
    <category>
      <category>Agents that produce neuromuscular block (indirect)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anions</category>
      <mesh-id>D000838</mesh-id>
    </category>
    <category>
      <category>Electrolytes</category>
      <mesh-id>D004573</mesh-id>
    </category>
    <category>
      <category>Ions</category>
      <mesh-id>D007477</mesh-id>
    </category>
    <category>
      <category>Minerals</category>
      <mesh-id>D008903</mesh-id>
    </category>
    <category>
      <category>Oxides</category>
      <mesh-id>D010087</mesh-id>
    </category>
    <category>
      <category>Oxygen Compounds</category>
      <mesh-id>D017601</mesh-id>
    </category>
    <category>
      <category>Pharmaceutic Aids</category>
      <mesh-id>D010592</mesh-id>
    </category>
    <category>
      <category>Silicon Compounds</category>
      <mesh-id>D017655</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB11230.pdf?1525106535</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB11230.pdf?1525106899</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>The therapeutic efficacy of Decamethonium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The therapeutic efficacy of Vecuronium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>The therapeutic efficacy of Pyrantel can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The therapeutic efficacy of Gallamine can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Doxycycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Piperacillin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Framycetin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Vancomycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Chloroquine is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium sulfate is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tobramycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Tetracycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Gentamicin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Quinidine is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Netilmicin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Streptomycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Colistimethate is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Kanamycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Dantrolene is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Rolitetracycline is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium oxide is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium cation is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Paromomycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01627</drugbank-id>
      <name>Lincomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Ribostamycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Geneticin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Apramycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Gentamicin C1a is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Neamine is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Arbekacin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06827</drugbank-id>
      <name>Viomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Puromycin is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium hydroxide is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium trisilicate is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium chloride is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09409</drugbank-id>
      <name>Magnesium acetate tetrahydrate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium acetate tetrahydrate is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium carbonate is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium citrate is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium glycinate is combined with Magnesium Aluminum Silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Dihydrostreptomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Hygromycin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Sisomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Plazomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Magnesium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Penimepicycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Dibekacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Micronomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13359</drugbank-id>
      <name>Magnesium aspartate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Magnesium aspartate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Isepamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Bekanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13749</drugbank-id>
      <name>Magnesium gluconate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Magnesium gluconate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13786</drugbank-id>
      <name>Magnesium orotate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Magnesium orotate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13862</drugbank-id>
      <name>Magnesium phosphate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Magnesium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13996</drugbank-id>
      <name>Magnesium acetate</name>
      <description>The risk or severity of neuromuscular blockade can be increased when Magnesium Aluminum Silicate is combined with Magnesium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00042</drugbank-id>
      <name>Botulinum Toxin Type B</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00083</drugbank-id>
      <name>Botulinum toxin type A</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum toxin type A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08837</drugbank-id>
      <name>Tetraethylammonium</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Tetraethylammonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08999</drugbank-id>
      <name>Cyclopentamine</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Cyclopentamine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties/>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Insoluble</value>
      <source>MSDS</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Pyrope</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>